efimosfermin - Search News

Order byBest matchMost fresh

News

GSK to buy phase III-ready drug efimosfermin

GSK to buy liver disease drug for up to $2 billion

GSK will buy efimosfermin, a liver disease drug in late-stage trials, for up to $2 billion from U.S. biotechnology firm Boston Pharmaceuticals, the British drugmaker said on Wednesday. Efimosfermin, a monthly subcutaneous injection,

Continue reading

· 13h · on MSN

GSK buys liver drug from Boston Pharmaceuticals for up to $2 billion

· 21h · on MSN

GSK to buy phase III-ready drug efimosfermin from Boston Pharmaceuticals for as much as $2B

22h

GSK to buy efimosfermin for up to $2 billion

GSK will buy efimosfermin, a specialty medicine used to treat liver disease from Boston Pharmaceuticals, for up to $2 billion ...

Once-Monthly Efimosfermin Leads to Significant MASH Improvement in Phase 2 Trial

Once-monthly efimosfermin alfa prescribed for metabolic dysfunction–associated steatohepatitis with F2 and F3 fibrosis ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results